Comparative Study of the Protective Effect of Metformin and Sitagliptin against Doxorubicin-Induced Cardiotoxicity in Rats

Mahmoud M. Kamel, Lubna Omar El-Farouk, A. Osman, O. Khorshid, Mohamed El Shabrawy-Abdo
{"title":"Comparative Study of the Protective Effect of Metformin and Sitagliptin against Doxorubicin-Induced Cardiotoxicity in Rats","authors":"Mahmoud M. Kamel, Lubna Omar El-Farouk, A. Osman, O. Khorshid, Mohamed El Shabrawy-Abdo","doi":"10.4172/2167-065X.1000174","DOIUrl":null,"url":null,"abstract":"Background and aim: Cancer patients treated with doxorubicin are at high risk to develop cardiotoxicity and hyperglycemia. The present study was designed to compare the effect of the two anti-hyperglycemia drugs; metformin and Sitagliptin, in the prevention of doxorubicin-induced cardiotoxicity in rats. \nMethods: Cardiotoxicity was induced in male Wistar rats by intraperitoneal injection of cumulative dose of doxorubicin (15 mg/kg over 3 weeks). Metformin or sitagliptin was administrated orally concomitant with intraperitoneal doxorubicin for 3 weeks. Mean body weight, systolic blood pressure, electrocardiographic changes, serum lactate dehydrogenase and creatine kinase-myocardium band, blood glucose and cardiac malondialdhyde level, cardiac histopathological examination and in vitro cardiac contractility in response to isoprenaline were be assessed. \nResults: Doxorubicin induced marked cardiotoxicity evidenced by significant deterioration in body weight, systolic blood pressure and heart rate, elevation of ST segment, prolongation of QT interval, elevation in the serum level of creatine kinase-myocardiac band and lactate dehydrogenase, blood glucose and cardiac malondialdhyde level and reduced in vitro cardiac contractility in response to isoprenaline compared to control untreated rats. These changes were associated with histopathological evidence of cardiotoxicity. Administration of either metformin or sitagliptin with doxorubicin resulted in significant improvement in all tested parameters compared with doxorubicin treated rats. Metformin treated rats showed more significant improvement in systolic blood pressure, ST segment elevation, serum enzymes, cardiac malondialdhyde, histopathological finding and in vitro cardiac contractility than sitagliptin treated rats. \nConclusion: The present study showed that metformin ameliorated doxorubicin-induced cardiotoxicity better than sitagliptin.","PeriodicalId":10410,"journal":{"name":"Clinical Pharmacology & Biopharmaceutics","volume":"40 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2017-08-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"6","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Pharmacology & Biopharmaceutics","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4172/2167-065X.1000174","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 6

Abstract

Background and aim: Cancer patients treated with doxorubicin are at high risk to develop cardiotoxicity and hyperglycemia. The present study was designed to compare the effect of the two anti-hyperglycemia drugs; metformin and Sitagliptin, in the prevention of doxorubicin-induced cardiotoxicity in rats. Methods: Cardiotoxicity was induced in male Wistar rats by intraperitoneal injection of cumulative dose of doxorubicin (15 mg/kg over 3 weeks). Metformin or sitagliptin was administrated orally concomitant with intraperitoneal doxorubicin for 3 weeks. Mean body weight, systolic blood pressure, electrocardiographic changes, serum lactate dehydrogenase and creatine kinase-myocardium band, blood glucose and cardiac malondialdhyde level, cardiac histopathological examination and in vitro cardiac contractility in response to isoprenaline were be assessed. Results: Doxorubicin induced marked cardiotoxicity evidenced by significant deterioration in body weight, systolic blood pressure and heart rate, elevation of ST segment, prolongation of QT interval, elevation in the serum level of creatine kinase-myocardiac band and lactate dehydrogenase, blood glucose and cardiac malondialdhyde level and reduced in vitro cardiac contractility in response to isoprenaline compared to control untreated rats. These changes were associated with histopathological evidence of cardiotoxicity. Administration of either metformin or sitagliptin with doxorubicin resulted in significant improvement in all tested parameters compared with doxorubicin treated rats. Metformin treated rats showed more significant improvement in systolic blood pressure, ST segment elevation, serum enzymes, cardiac malondialdhyde, histopathological finding and in vitro cardiac contractility than sitagliptin treated rats. Conclusion: The present study showed that metformin ameliorated doxorubicin-induced cardiotoxicity better than sitagliptin.
二甲双胍与西格列汀对阿霉素致大鼠心脏毒性保护作用的比较研究
背景和目的:接受阿霉素治疗的癌症患者发生心脏毒性和高血糖的风险很高。本研究旨在比较两种抗高血糖药物的效果;二甲双胍和西格列汀在预防阿霉素引起的大鼠心脏毒性中的作用。方法:雄性Wistar大鼠腹腔注射累积剂量阿霉素(15mg /kg,持续3周)致心脏毒性。二甲双胍或西格列汀口服,同时腹腔注射阿霉素3周。评估各组平均体重、收缩压、心电图变化、血清乳酸脱氢酶和肌酸激酶-心肌带、血糖和心脏丙二醛水平、心脏组织病理学检查和异丙肾上腺素对体外心脏收缩力的影响。结果:阿霉素诱导了明显的心脏毒性,表现为与对照组相比,异丙肾上腺素对大鼠的体重、收缩压和心率明显恶化,ST段升高,QT间期延长,血清肌酸激酶-心肌带水平和乳酸脱氢酶水平升高,血糖和心脏丙二醛水平升高,体外心脏收缩力降低。这些变化与心脏毒性的组织病理学证据有关。与阿霉素治疗的大鼠相比,二甲双胍或西格列汀与阿霉素联合用药可显著改善所有测试参数。与西格列汀治疗大鼠相比,二甲双胍治疗大鼠在收缩压、ST段抬高、血清酶、心脏丙二醛、组织病理学检查和体外心脏收缩力方面均有更显著的改善。结论:二甲双胍比西格列汀更能改善阿霉素引起的心脏毒性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信